Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
- PMID: 18593923
- PMCID: PMC4445363
- DOI: 10.1158/0008-5472.CAN-07-5744
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
Erratum in
- Cancer Res. 2008 Sep 1;68(17):7246. Song, Lynda L [added]
Abstract
High expression of Notch-1 and Jagged-1 mRNA correlates with poor prognosis in breast cancer. Elucidating the cross-talk between Notch and other major breast cancer pathways is necessary to determine which patients may benefit from Notch inhibitors, which agents should be combined with them, and which biomarkers indicate Notch activity in vivo. We explored expression of Notch receptors and ligands in clinical specimens, as well as activity, regulation, and effectors of Notch signaling using cell lines and xenografts. Ductal and lobular carcinomas commonly expressed Notch-1, Notch-4, and Jagged-1 at variable levels. However, in breast cancer cell lines, Notch-induced transcriptional activity did not correlate with Notch receptor levels and was highest in estrogen receptor alpha-negative (ERalpha(-)), Her2/Neu nonoverexpressing cells. In ERalpha(+) cells, estradiol inhibited Notch activity and Notch-1(IC) nuclear levels and affected Notch-1 cellular distribution. Tamoxifen and raloxifene blocked this effect, reactivating Notch. Notch-1 induced Notch-4. Notch-4 expression in clinical specimens correlated with proliferation (Ki67). In MDA-MB231 (ERalpha(-)) cells, Notch-1 knockdown or gamma-secretase inhibition decreased cyclins A and B1, causing G(2) arrest, p53-independent induction of NOXA, and death. In T47D:A18 (ERalpha(+)) cells, the same targets were affected, and Notch inhibition potentiated the effects of tamoxifen. In vivo, gamma-secretase inhibitor treatment arrested the growth of MDA-MB231 tumors and, in combination with tamoxifen, caused regression of T47D:A18 tumors. Our data indicate that combinations of antiestrogens and Notch inhibitors may be effective in ERalpha(+) breast cancers and that Notch signaling is a potential therapeutic target in ERalpha(-) breast cancers.
Figures






Similar articles
-
Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.Breast Cancer Res. 2014 Jun 11;16(3):R62. doi: 10.1186/bcr3675. Breast Cancer Res. 2014. PMID: 24919951 Free PMC article.
-
Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.Mol Cancer. 2013 May 1;12:34. doi: 10.1186/1476-4598-12-34. Mol Cancer. 2013. Retraction in: Mol Cancer. 2017 Jul 17;16(1):121. doi: 10.1186/s12943-017-0697-5. PMID: 23634843 Free PMC article. Retracted.
-
NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900. Breast Cancer Res. 2011. PMID: 21679465 Free PMC article.
-
Breast cancer stem cells: something out of notching?Cancer Res. 2010 Nov 15;70(22):8973-6. doi: 10.1158/0008-5472.CAN-10-1559. Epub 2010 Nov 2. Cancer Res. 2010. PMID: 21045140 Review.
-
Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.Clin Cancer Res. 2015 Mar 1;21(5):955-61. doi: 10.1158/1078-0432.CCR-14-0809. Epub 2014 Nov 11. Clin Cancer Res. 2015. PMID: 25388163 Free PMC article. Review.
Cited by
-
Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers.Am J Transl Res. 2013 Apr 19;5(3):368-78. Print 2013. Am J Transl Res. 2013. PMID: 23634247 Free PMC article.
-
Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells.Breast Cancer Res Treat. 2012 Nov;136(1):45-56. doi: 10.1007/s10549-012-2239-6. Epub 2012 Sep 11. Breast Cancer Res Treat. 2012. PMID: 22965833 Free PMC article.
-
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.Oncotarget. 2015 Jun 30;6(18):16559-72. doi: 10.18632/oncotarget.4116. Oncotarget. 2015. PMID: 26041884 Free PMC article.
-
Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.Mol Ther. 2011 Aug;19(8):1538-46. doi: 10.1038/mt.2011.105. Epub 2011 May 31. Mol Ther. 2011. PMID: 21629222 Free PMC article.
-
17β-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells.PLoS One. 2013 Aug 13;8(8):e71440. doi: 10.1371/journal.pone.0071440. eCollection 2013. PLoS One. 2013. PMID: 23967210 Free PMC article.
References
-
- Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med. 2006;6:905–18. - PubMed
-
- Miele L. Notch signaling. Clin Cancer Res. 2006;12:1074–9. - PubMed
-
- Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 2007;17:52–9. - PubMed
-
- Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71. - PubMed
-
- Malyukova A, Dohda T, von der LN, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007;67:5611–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous